

# Olivier Gremy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6285898/publications.pdf>

Version: 2024-02-01

28  
papers

390  
citations

687220

13  
h-index

752573

20  
g-index

28  
all docs

28  
docs citations

28  
times ranked

336  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduction of Peroxisome Proliferation-Activated Receptor $\hat{1}^3$ Expression by $\hat{1}^3$ -Irradiation as a Mechanism Contributing to Inflammatory Response in Rat Colon: Modulation by the 5-Aminosalicylic Acid Agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 911-920.	1.3	48
2	Acute and persisting Th2-like immune response after fractionated colorectal $\hat{1}^3$ -irradiation. <i>World Journal of Gastroenterology</i> , 2008, 14, 7075.	1.4	41
3	Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action. <i>Radiation Research</i> , 2016, 185, 568-579.	0.7	32
4	Caffeic acid phenethyl ester modifies the Th1/Th2 balance in ileal mucosa after $\hat{1}^3$ -irradiation in the rat by modulating the cytokine pattern. <i>World Journal of Gastroenterology</i> , 2006, 12, 4996.	1.4	28
5	STRUCTURE OF A SINGLE MODEL TO DESCRIBE PLUTONIUM AND AMERICIUM DECORPORATION BY DTPA TREATMENTS. <i>Health Physics</i> , 2010, 99, 553-559.	0.3	24
6	Preferential Decorporation of Americium by Pulmonary Administration of DTPA Dry Powder after Inhalation of Aged PuO <sub>2</sub> Containing Americium in Rats. <i>Radiation Research</i> , 2010, 174, 637-644.	0.7	22
7	Plutonium Behavior after Pulmonary Administration According to Solubility Properties, and Consequences on Alveolar Macrophage Activation. <i>Journal of Radiation Research</i> , 2012, 53, 184-194.	0.8	22
8	Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium after Systemic, Liver or Pulmonary Contamination of Rats Associated with Ca-DTPA Treatments. <i>Radiation Research</i> , 2009, 171, 674-686.	0.7	19
9	Delivery of DTPA through Liposomes as a Good Strategy for Enhancing Plutonium Decorporation Regardless of Treatment Regimen. <i>Radiation Research</i> , 2018, 189, 477-489.	0.7	19
10	Drosophila Translational Elongation Factor-1 $\hat{1}^3$ Is Modified in Response to DOA Kinase Activity and Is Essential for Cellular Viability. <i>Genetics</i> , 2010, 184, 141-154.	1.2	18
11	Decorporation Approach Following Rat Lung Contamination with a Moderately Soluble Compound of Plutonium Using Local and Systemic Ca-DTPA Combined Chelation. <i>Radiation Research</i> , 2012, 178, 217-223.	0.7	17
12	<i>In Vitro</i> and <i>In Vivo</i> Assessment of Plutonium Speciation and Decorporation in Blood and Target Retention Tissues after a Systemic Contamination followed by an Early Treatment with DTPA. <i>Radiation Research</i> , 2008, 170, 208-215.	0.7	16
13	Medical countermeasures after a radiological event: An update from the CATO project. <i>International Journal of Radiation Biology</i> , 2014, 90, 1043-1047.	1.0	14
14	Chelation Treatment by Early Inhalation of Liquid Aerosol DTPA for Removing Plutonium after Rat Lung Contamination. <i>Radiation Research</i> , 2019, 192, 630.	0.7	14
15	Activation of Alveolar Macrophages after Plutonium Oxide Inhalation in Rats: Involvement in the Early Inflammatory Response. <i>Radiation Research</i> , 2008, 170, 591-603.	0.7	12
16	ISOTOPIC AND ELEMENTAL COMPOSITION OF PLUTONIUM/AMERICIUM OXIDES INFLUENCE PULMONARY AND EXTRA-PULMONARY DISTRIBUTION AFTER INHALATION IN RATS. <i>Health Physics</i> , 2010, 99, 380-387.	0.3	11
17	MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy. <i>Radiation Protection Dosimetry</i> , 2011, 144, 371-375.	0.4	6
18	Decorporation Approach after Rat Lung Contamination with Plutonium: Evaluation of the Key Parameters Influencing the Efficacy of a Protracted Chelation Treatment. <i>Radiation Research</i> , 2017, 188, 632-641.	0.7	6

#	ARTICLE	IF	CITATIONS
19	Comparison of Local and Systemic DTPA Treatment Efficacy According to Actinide Physicochemical Properties Following Lung or Wound Contamination in the Rat. <i>Frontiers in Pharmacology</i> , 2021, 12, 635792.	1.6	6
20	Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake. <i>Health Physics</i> , 2021, 121, 494-505.	0.3	4
21	Comments on "Improved Modeling of Plutonium-DTPA Decorporation" ( <i>Radiat Res</i> 2019; 191:201-10). <i>Radiation Research</i> , 2019, 192, 680.	0.7	4
22	Excretion of Pu-238 during Long-term Chelation Therapy by Repeated DTPA Inhalation. <i>Health Physics</i> , 2022, 123, 197-207.	0.3	3
23	Americium biodistribution in rats after wound contamination with different physicochemical forms in the presence or absence of plutonium: analyses using STATBIODIS. <i>Journal of Radiological Protection</i> , 2019, 39, 707-738.	0.6	2
24	From in vivo to in vitro models to assess bioavailability properties of Plutonium compounds. <i>BIO Web of Conferences</i> , 2019, 14, 02007.	0.1	1
25	DTPA-Coated Liposomes as a New Delivery Vehicle for Plutonium Decorporation. <i>Radiation Research</i> , 2020, 195, 77-92.	0.7	1
26	Modélisation de la décorporation du Pu/am par le dtpa. <i>Radioprotection</i> , 2009, 44, 431-446.	0.5	0
27	Medical countermeasures against radionuclide contamination: An overview. <i>BIO Web of Conferences</i> , 2019, 14, 06001.	0.1	0
28	Modelling DTPA decorporation of Am in rats. <i>BIO Web of Conferences</i> , 2019, 14, 06003.	0.1	0